Neurocrine Biosciences Launches INGREZZA SPRINKLE Capsules
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences has launched INGREZZA SPRINKLE capsules, a new formulation of its existing drug INGREZZA, designed to make it easier for patients with swallowing difficulties to take their medication.
July 18, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences has introduced INGREZZA SPRINKLE capsules, a new formulation of its drug INGREZZA, aimed at helping patients with swallowing difficulties.
The launch of INGREZZA SPRINKLE capsules is likely to positively impact Neurocrine Biosciences' stock in the short term as it addresses a specific patient need, potentially increasing the drug's market reach and sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100